Is the end of obesity in sight?

Of all the shocking predictions from Livewire Live 2023, this was the prediction which garnered the most comments from readers. Its orator, Dr David Allen, Head of Long Short Strategies at Plato Investment Management, wasn't so enthused about what it might mean for some of his preferred fast foods. 

But he was enthusiastic about what it would mean for investors in companies like the drug companies Novo Nordisk (makers of Wegovy) and Eli Lilly (NASDAQ: LLY) (makers of Mounjaro, expected to be approved towards the end of 2023). These are, in Allen's view, the clear winners as science looks to move one step closer to eliminating obesity. 

In addition to his overarching prediction, Allen argued that companies which offer obesity-adjacent treatments like Medifast (NYSE: MED), Dexcom (NASDAQ: DXCM), Resmed (ASX: RMD) and Insulet (NASDAQ: PODD) are also in trouble due to the work of Novo Nordisk and Eli Lilly. Whereas Weight Watchers (NASDAQ: WW) reversed this trend by investing in a tele-health company earlier this year that only does Wegovy consultations.

Watch Allen present his shocking prediction and its implications for the above companies. 

Managed Fund

Plato Global Alpha Fund

Global Shares

View

Want access to stock ideas?

You told us you’re looking for an edge in investing. As the principal sponsor of Livewire Live 2023, Bell Direct is giving you exclusive access to 3 Bell Potter stock reports each week PLUS the chance to win a share of 3 million Velocity Frequent Flyer Points. Get your reports and enter the Velocity competition now. Competition ends 31 October 2023. Entry conditions and eligibility criteria apply.

Get my 3 Bell Potter stock reports now.